Y0000492

オキシコドン塩酸塩

Name: オキシコドン 塩酸塩
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

ログインで組織・契約価格をご覧ください。

サイズを選択してください

この商品について

実験式（ヒル表記法）:

C₁₈H₂₁NO₄ · HCl

CAS番号:

124-90-3

分子量:

351.82

NACRES:

NA.24

PubChem Substance ID:

329830982

UNSPSC Code:

41116107

MDL number:

MFCD00137583

主要文書

すべての文書を表示

テクニカルサービス

お困りのことがあれば、経験豊富なテクニカルサービスチームがお客様をサポートします。

お手伝いします

テクニカルサービス

お困りのことがあれば、経験豊富なテクニカルサービスチームがお客様をサポートします。

お手伝いします

InChI

1S/C18H21NO4.ClH/c1-19-8-7-17-14-10-3-4-12(22-2)15(14)23-16(17)11(20)5-6-18(17,21)13(19)9-10;/h3-4,13,16,21H,5-9H2,1-2H3;1H/t13-,16+,17+,18-;/m1./s1

SMILES string

Cl.[H][C@@]12Oc3c(OC)ccc4C[C@H]5N(C)CC[C@@]1(c34)[C@@]5(O)CCC2=O

InChI key

MUZQPDBAOYKNLO-RKXJKUSZSA-N

grade

pharmaceutical primary standard

API family

oxycodone

manufacturer/tradename

EDQM

drug control

USDEA Schedule I; regulated under CDSA - not available from Sigma-Aldrich Canada; estupefaciente (Spain); Decreto Lei 15/93: Tabela IA (Portugal), kontrollierte Droge in Deutschland

Gene Information

human ... OPRM1(4988)

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

類似した製品をお探しですか？訪問製品比較ガイド

General description

この製品は薬局方標準品です。発行元の薬局方により製造・供給されています。MSDSを含む製品情報などの詳しい情報は、発行元の薬局方のウェブサイトよりご確認ください。

Application

Oxycodone hydrochloride EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

μ and κ opioid receptor agonist.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Legal Information

German
Dieses Produkt fällt unter das Betäubungsmittelgesetz (BtMG). Für eine Bestellung dieses Produktes ist eine Erlaubnis nach § 3 BtMG zwingend erforderlich, es sei denn, es greift eine Ausnahme von der Erlaubnispflicht nach § 4 oder § 26 BtMG.

English
This product is subject to the German Narcotics Act. A permit under Section 3 of the German Narcotics Act is mandatory for ordering this product unless an exemption from the permit requirement under Section 4 or Section 26 of the German Narcotics Act applies.

pictograms

GHS07

signalword

Warning

hcodes

H302,H336

pcodes

P261 - P264 - P270 - P271 - P301 + P312 - P304 + P340 + P312

Hazard Classifications

Acute Tox. 4 Oral - STOT SE 3

target_organs

Central nervous system

保管分類

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

適用法令

試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。

Y0000492-1EA: + Y0000492:

jan

最新バージョンのいずれかを選択してください：

試験成績書（COA）

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 資料 section.

サポートが必要な場合は、お問い合わせくださいカスタマーサポート

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

Rapid dopamine transmission within the nucleus accumbens: dramatic difference between morphine and oxycodone delivery.

Caitlin M Vander Weele et al.

The European journal of neuroscience, 40(7), 3041-3054 (2014-09-12)

While most drugs of abuse increase dopamine neurotransmission, rapid neurochemical measurements show that different drugs evoke distinct dopamine release patterns within the nucleus accumbens. Rapid changes in dopamine concentration following psychostimulant administration have been well studied; however, such changes have

Abuse potential of intravenous oxycodone/naloxone solution in nondependent recreational drug users.

Salvatore V Colucci et al.

Clinical drug investigation, 34(6), 421-429 (2014-04-24)

Abuse of opioid analgesics has become a public health issue. Some opioid abusers use intravenous administration to increase the magnitude of positive reinforcing effects. Intravenous co-administration of oxycodone with naloxone, an opioid antagonist, may reduce these rewarding effects and discourage

Compulsive-like responding for opioid analgesics in rats with extended access.

Carrie L Wade et al.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 40(2), 421-428 (2014-07-26)

The abuse of prescription opioids that are used for the treatment of chronic pain is a major public health concern, costing ∼$53.4 billion annually in lost wages, health-care costs, and criminal costs. Although opioids remain a first-line therapy for the

A preclinical physiological assay to test modulation of knee joint pain in the spinal cord: effects of oxycodone and naproxen.

Jason A Miranda et al.

PloS one, 9(8), e106108-e106108 (2014-08-27)

Sensory processing in the spinal cord during disease states can reveal mechanisms for novel treatments, yet very little is known about pain processing at this level in the most commonly used animal models of articular pain. Here we report a

Establishment of opioid-induced rewarding effects under oxaliplatin- and Paclitaxel-induced neuropathy in rats.

Tomohisa Mori et al.

Journal of pharmacological sciences, 126(1), 47-55 (2014-08-22)

The rewarding effects of μ-receptor agonists can be suppressed under several pain conditions. We recently showed that clinically used μ-receptor agonists possess efficacies for relieving the neuropathic pain induced by chemotherapeutic drug in rats; however, it is possible that the

オキシコドン 塩酸塩

European Pharmacopoeia (EP) Reference Standard

サイズを選択してください

この商品について

主要文書

特性

InChI

SMILES string

InChI key

grade

API family

manufacturer/tradename

drug control

Gene Information

application(s)

format

storage temp.

詳細

General description

Application

Biochem/physiol Actions

Packaging

Other Notes

Legal Information

安全性情報

pictograms

signalword

hcodes

pcodes

Hazard Classifications

target_organs

保管分類

wgk

flash_point_f

flash_point_c

適用法令

Y0000492-1EA: + Y0000492:

資料

試験成績書（COA）

以前この製品を購入いただいたことがある場合

参考文献

テクニカルサービス

オキシコドン塩酸塩